Published in
Elsevier, The Lancet Oncology, 10(20), p. 1370-1385, 2019
DOI: 10.1016/s1470-2045(19)30413-9
Links
Tools
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Journal article published in 2019 by
Robert J. Motzer,
Brian I. Rini,
David F. McDermott,
Osvaldo Arén Frontera,
Hans J. Hammers,
Michael A. Carducci,
Pamela Salman,
Bernard Escudier,
Benoit Beuselinck,
Asim Amin,
Camillo Porta,
Saby George 
,
Victoria Neiman,
Sergio Bracarda,
Scott S. Tykodi
and other authors.
,
Victoria Neiman,
Sergio Bracarda,
Scott S. Tykodi
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 